DOSE IN NORMAL RENAL FUNCTION
3.2 g every 6–8 hours, increased to every 4 hours in severe infections
PHARMACOKINETICS
DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
>30 3.2 g every 8 hours 10–30 1.6 g every 8 hours
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
ADMINISTRATION
Reconstition
With 10 mL water for injection and add to 100 mL glucose 5%
Route
IV
Rate of Administration
30–40 minutes
Comments
Each 3.2 g of ticarcillin/clavulanic acid contains 16 mmol of sodium and 1 mmol of potassium
OTHER INFORMATION
CSM has advised that cholestatic jaundice may occur if treatment exceeds a period of 14 days and can present up to 6 weeks after treatment has been stopped. The incidence of cholestatic jaundice occurring with Timentin is higher in males than in females and is particularly prevalent in men over the age of 65 years